William Dai has more than 20 years of experience in corporate finance, mergers and acquisitions, and capital markets in both China and the U.S. He has held senior executive roles at major U.S. multinational companies. In those roles, William was responsible for overall execution and was held accountable to the highest ethical standards in his business dealings.
He is well-respected among financial and investment circles, and is a recognized leader in the industry. In addition, due to his hands-on experience leading multiple large international medical device companies, he has a very in-depth knowledge of the medical device industry and its market dynamics. William Dai holds a master’s degree in business administration with an emphasis on finance from Michigan State University.
Shawn Hingtgen, PhD
Shawn is the CSO and founder of Falcon, an Associate Professor in the UNC Eshelman School of Pharmacy’s Division of Molecular Pharmaceutics and Pharmacoengineering, and an assistant professor in the Department of Neurosurgery at the UNC School of Medicine. His research is focused on combining advancements in cell engineering, biomedical engineering, and cancer therapy to generate novel engineered cell therapies for cancer. His team was the first to show that skin cells could be directly converted into cells that seek out and kill cancer and has made significant contributions to the generation of scaffolds for cell-based cancer therapy, and new cancer models that more accurately reflect the clinical scenario.
In 2014 he received the Young Investigator Award from the Society for Neuro-Oncology and the UNC Hettleman Prize for Scholarly and Artistic Achievement by Young Faculty in 2018. He is the author of over 30 refereed papers and articles that have been cited more than 700 times, as well as the inventor on multiple patents.
Shawn completed his undergraduate work and earned his Ph.D. in anatomy and cell biology from the University of Iowa. He then completed postdoctoral fellowships with Ralph Weissleder, M.D., Ph.D., and Khalid Shah, Ph.D., at Harvard Medical School and Massachusetts General Hospital in Boston.
Matthew G. Ewend, MD FACS
Dr. Matthew Ewend is the President of UNC Physicians and has responsibility for the overall physician enterprise of UNC Health Care System, a statewide network of 13 hospitals and more than 1,900 employed physicians across more than 600 practices. He also serves as UNC Health Care’s Chief Quality and Value Officer and is charged with planning and leading UNC’s quality improvement and population health initiatives.
In addition, Dr. Ewend is Chair of the Department of Neurosurgery at the UNC School of Medicine. He joined the faculty in 1997 after completing medical school, neurosurgery residency, and a brain tumor fellowship at The Johns Hopkins School of Medicine and The Johns Hopkins Hospital. Dr. Ewend’s clinical interests center on endoscopic and minimally invasive treatment of brain tumors, especially pituitary tumors, skull base tumors, and metastases. His research interest centers on developing cell based therapies for treatment of brain tumors.
Sallie Shuping Russell
Sallie Shuping Russell has over 35 years investing in venture capital, growth equity, buyouts, and other private assets. She retired in 2017, having served most recently as a managing director at BlackRock, in its Private Equity Partners group. Since then she has been an active private investor. Prior to joining BlackRock she was a general partner with Intersouth Partners, focusing primarily on life science companies. Ms. Shuping-Russell was also a founder of DUMAC, which invests the endowment and certain retirement assets of Duke University. Over 15 years at Duke she built one of the most successful institutional venture and private equity portfolios, leading Duke to the top performers among endowments.
Ms. Shuping-Russell has served on the boards of many venture-backed companies as well as several leading non-profit organizations. Her most active roles are as vice president of the UNC Investment Fund and formerly as a trustee of UNC-CH and director of UNC Healthcare.
John Maslowski, PhD
Mr. Maslowski serves as Fibrocell’s President and Chief Executive Officer. Prior to that, he was Senior Vice President of Scientific Affairs, with oversight of research and development, clinical and regulatory affairs. Previously, he was Vice President of Operations with responsibility for manufacturing and quality operations.
Prior to joining Fibrocell, Mr. Maslowski held various positions at Wyeth Pharmaceuticals, Inc. (now Pfizer, Inc.), eventually serving as Quality Assurance Manager. Prior to joining Wyeth, Mr. Maslowski held various positions with Merck & Co. and Teva. Mr. Maslowski earned a B.S. in Biology from the Ursinus College and an M.S. in Biology from Villanova University.